Trials / Completed
CompletedNCT00326248
Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women
A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50mg Oral Dosing With the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 482 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW679769 (casopitant) |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2006-07-01
- Completion
- 2006-07-01
- First posted
- 2006-05-16
- Last updated
- 2016-10-26
Locations
58 sites across 11 countries: United States, Canada, France, Germany, Hong Kong, Hungary, Ireland, Pakistan, Philippines, Thailand, United Kingdom
Source: ClinicalTrials.gov record NCT00326248. Inclusion in this directory is not an endorsement.